NCT02982486 2017-11-01A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaAssaf-Harofeh Medical CenterPhase 2 Unknown60 enrolled
NCT01643278 2017-01-10Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are MetastaticNational Cancer Institute (NCI)Phase 1 Completed29 enrolled